Curio Wealth’s Recursion Pharmaceuticals RXRX Stock Holding History

Curio Wealth’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-273	Closed	-$838	–	929
2026 Q1	$838	Buy	+273	New	+$1.05K	﹤0.01%	409

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Curio Wealth's RXRX Position: Q2 2026 in Review

Curio Wealth sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 273 shares — an estimated $838 sold.

Curio Wealth first reported a position in RXRX in Q1 2026 and held it in 1 quarter. The position peaked at $838 in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Curio Wealth reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Curio Wealth sold 273 Recursion Pharmaceuticals shares in Q2 2026, an estimated $838.
Curio Wealth first reported a position in Recursion Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Curio Wealth's Recursion Pharmaceuticals position peaked at $838 in Q1 2026.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Curio Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.